TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33555374

Group type: EXPERIMENTAL
Intervention: Fibre-enriched Leberkas meal (19.2 g of wheat fibre and resistant dextrin, fat- and energy-reduced by 30%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Leberkas meal
Number of subjects: 20
Study: 35470188

Group type: EXPERIMENTAL
Intervention: Primary radiotherapy combined with S‐1 and nedaplatin chemotherapy (50.4 Gy + 4-6 cycles of S-1 and NPD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: S‐1 and nedaplatin chemotherapy (4-6 cycles)
Number of subjects: 180
Study: 34810107

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training + sensorimotor physical therapy (45 min sensorimotor + 15 min inspiratory muscle training for 18 sessions over six weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (45 min sensorimotor training session, three times a week over six weeks)
Number of subjects: 40
Study: 35162053

Group type: EXPERIMENTAL
Intervention: Variable unilateral horizontal movements (VUH, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unilateral lateral movements (VUL, n = 12)
Number of subjects: 24
Study: 34041615

Group type: EXPERIMENTAL
Intervention: Music therapy (six-step music therapy), n=50
Number of subjects: 100
Study: 32886650

Group type: EXPERIMENTAL
Intervention: Actiwatch 2 (AW2)
Number of subjects: 50
Study: 35030278

Group type: EXPERIMENTAL
Intervention: OCS
Number of subjects: 38

Group type: COMPARATOR
Intervention: CS
Number of subjects: 38
Study: 32427726

Group type: EXPERIMENTAL
Intervention: Ocular surgery (specifically strabismus, cornea, and glaucoma surgeries)
Number of subjects: 8297

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 8297

Group type: EXPERIMENTAL
Intervention: Type II diabetes
Number of subjects: 8297
Study: 32205463

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (30 Gy in 10 fractions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (27 Gy in 3 fractions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (historical data of nivolumab and ipilimumab alone)
Number of subjects: 20
Study: 35028919

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no WBV)
Number of subjects: 67
Study: 34061144

Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab (375 mg/m2/wk, 4 doses)
Number of subjects: 140

Group type: COMPARATOR
Intervention: High-dose prednisolone (1 mg/kg/d) plus rituximab
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab
Number of subjects: 140
Study: 34987204

Group type: EXPERIMENTAL
Intervention: Coach-directed behavioral weight loss on a DASH diet
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Self-directed care (control)
Number of subjects: 121
Study: 32334034

Group type: EXPERIMENTAL
Intervention: Concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2) plus IG‐IMRT (45‐47.6 Gy, 25‐28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2‐59.4 Gy, 28 fractions)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IG‐IMRT with concurrent chemotherapy
Number of subjects: 35
Study: 33092420

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (cord clamped in 30–45 s)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (cord clamped in 10–15 s)
Number of subjects: 148
Study: 35109906

Group type: EXPERIMENTAL
Intervention: Topical hydrogen peroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical fusidic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple wound care
Number of subjects: 0
Study: 33171113

Group type: EXPERIMENTAL
Intervention: Leukocyte‐ and platelet‐rich fibrin (L‐PRF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Blood clot
Number of subjects: 16
Study: 35236391

Group type: EXPERIMENTAL
Intervention: morphine sulphate 5 mg twice daily for 14 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo twice daily
Number of subjects: 44
Study: 32961255

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Number of subjects: 645
Study: 32633901

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) - eight sessions of twice-weekly training (n=49)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham training (n=21)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 79
Study: 33246252

Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 14
Study: 32216084

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) administered in two equally divided doses over two nights; dose 1 was half of dose 2, administered > 2 hours after the evening meal and ≥ 4 hours after dose 1.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Population PK model established combining current study data with prior data from adults (132 healthy volunteers and 13 with narcolepsy).
Number of subjects: 29
Study: 34519560

Group type: EXPERIMENTAL
Intervention: Data Mountain delivered in small groups
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Data Mountain delivered individually
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 81
Study: 34421047

Group type: EXPERIMENTAL
Intervention: Storytelling-based intervention (ST)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Didactic learning (DL)
Number of subjects: 585
Study: 36054974

Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl (4 mg BID to 8 mg TID over 3 weeks)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (matched doses)
Number of subjects: 94
Study: 36041912

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 32503392

Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Videoconferencing (VC) group
Number of subjects: 18
Study: 32108274

Group type: EXPERIMENTAL
Intervention: Item imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggregate imputation
Number of subjects: 0
Study: 36130482

Group type: EXPERIMENTAL
Intervention: High fructose feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 34294219

Group type: EXPERIMENTAL
Intervention: Anterior endonasal dacryorhinocystostomy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Posterior endonasal dacryorhinocystostomy (Group B)
Number of subjects: 30
Study: 32803720

Group type: EXPERIMENTAL
Intervention: First-line doublet chemotherapy with bevacizumab
Number of subjects: 867

Group type: COMPARATOR
Intervention: First-line doublet chemotherapy without bevacizumab
Number of subjects: 867
Study: 35831055

Group type: EXPERIMENTAL
Intervention: Multimedia information (MMI) group; n=681
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Printed participant information sheet (PIS) group; n=728
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: MMI group
Number of subjects: 1409

Group type: COMPARATOR
Intervention: PIS group
Number of subjects: 1409
Study: 33246371

Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program delivered via video conferencing technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program delivered via inmate co-facilitated formats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program with greater program dosage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Program completion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional classroom administration of the Thinking for a Change program
Number of subjects: 0
Study: 32827441

Group type: EXPERIMENTAL
Intervention: Serum PTH levels
Number of subjects: 361194
Study: 36121664

Group type: EXPERIMENTAL
Intervention: Men with PSA ≥3 to 4 ng/ml
Number of subjects: 46495

Group type: EXPERIMENTAL
Intervention: Men with PIRADS score ≤ 2
Number of subjects: 46495

Group type: EXPERIMENTAL
Intervention: Men with a history of digital rectal examination or PSA testing prior to recruitment
Number of subjects: 46495
Study: 33611087

Group type: EXPERIMENTAL
Intervention: 10 mg regular, oral sustained-release morphine twice daily for four weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 32891871

Group type: EXPERIMENTAL
Intervention: tDCS to frontal (F4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tDCS to parietal (P4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tDCS alternating (P4–F4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham tDCS (P4 or F4)
Number of subjects: 80
Study: 34895843

Group type: EXPERIMENTAL
Intervention: Posaconazole (Group-2, n = 241)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Posaconazole with other antifungal prophylaxis (Group-3, n = 142)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Other antifungal prophylaxis (Group-4, n = 91)
Number of subjects: 677

Group type: COMPARATOR
Intervention: No antifungal prophylaxis (Group-1, n = 203)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: IFI occurrence
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: AML complete remission
Number of subjects: 677
Study: 32694343

Group type: EXPERIMENTAL
Intervention: Aerobic training (n=15)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance training (n=15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercise control (n=12)
Number of subjects: 42
Study: 35207411

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg administered orally for 12 weeks
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 32773216

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n=23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Propofol (n=24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Propofol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Anterior–posterior connectivity in the alpha band
Number of subjects: 47
Study: 35729025

Group type: COMPARATOR
Intervention: Ivermectin (Outpatient)
Number of subjects: 797285

Group type: COMPARATOR
Intervention: Ivermectin (Inpatient not requiring Intensive Care)
Number of subjects: 797285

Group type: COMPARATOR
Intervention: Ivermectin (Intensive care)
Number of subjects: 797285
Study: 34663379

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: XR-naltrexone treatment
Number of subjects: 41
Study: 32664070

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 120
Study: 34382427

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study: 33754649

Group type: EXPERIMENTAL
Intervention: T helper, T cytotoxic, and natural killer cell numbers
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: B cell numbers
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Unclass-switched and class-switched B cells
Number of subjects: 297
Study: 32219517

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) users
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CAM users declining conventional cancer therapy (CCT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Non-CAM users
Number of subjects: 500
Study: 34930689

Group type: EXPERIMENTAL
Intervention: Diabetes education based on learning modality (auditory, visual, tactile)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 60
Study: 33388183

Group type: EXPERIMENTAL
Intervention: Patient factors
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Family factors
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Societal factors
Number of subjects: 655
Study: 33361004

Group type: EXPERIMENTAL
Intervention: Fast multiscale neighbor embedding methods
Number of subjects: 0
Study: 34555865

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (LFD)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional dietary advice (TDA)
Number of subjects: 105
Study: 33663905

Group type: EXPERIMENTAL
Intervention: Simulation-based childbirth education (SBCE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 56
Study: 32311184

Group type: EXPERIMENTAL
Intervention: Buzzy® device (external cold and vibration)
Number of subjects: 60
Study: 36690924

Group type: EXPERIMENTAL
Intervention: Intermittent transcutaneous electrical stimulation (ITES)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous electrical stimulation (CTES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 33159163

Group type: EXPERIMENTAL
Intervention: Fish-oil (FO) supplementation (215 mg DHA + 285 mg EPA)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control corn-oil capsules (without n‐3 LCPs)
Number of subjects: 360
Study: 33488511

Group type: EXPERIMENTAL
Intervention: 12-month behavioral diabetes risk-reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34738484

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral-based Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)
Number of subjects: 14
Study: 37614053

Group type: EXPERIMENTAL
Intervention: Triple combination therapy (telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Dual combination therapy (telmisartan 40 mg/amlodipine 5 mg)
Number of subjects: 374
Study: 33787382

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal (ESW)
Number of subjects: 77
Study: 32098484

Group type: EXPERIMENTAL
Intervention: Using alcohol to cope
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and severity of alcohol consumption
Number of subjects: 110
Study: 34519685

Group type: EXPERIMENTAL
Intervention: Active priming stimulation (6-Hz rTMS at 80% resting motor threshold) followed by 1-Hz rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation followed by 1-Hz rTMS
Number of subjects: 30
Study: 32485663

Group type: EXPERIMENTAL
Intervention: Thai dance exercise on sand surface
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thai dance exercise on soft surface
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thai dance exercise on hard surface
Number of subjects: 120
Study: 35473650

Group type: EXPERIMENTAL
Intervention: Home-based telemental health group workshops (STEP-Home cognitive-behavioral group workshop)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Present-centered group therapy (TAU)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Home-based telemental health delivery (VC)
Number of subjects: 74
Study: 32197342

Group type: EXPERIMENTAL
Intervention: Five-day intensive holiday cooking program followed by six weeks of weekly meal kits with Facebook support groups
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 35239885

Group type: EXPERIMENTAL
Intervention: Integrated experiential learning of traditional Chinese and Western medicine
Number of subjects: 190

Group type: COMPARATOR
Intervention: Regular health education
Number of subjects: 190
Study: 32063629

Group type: EXPERIMENTAL
Intervention: Massage manipulation (20 min/day for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low back muscle exercise (3 sessions/day for 15 days)
Number of subjects: 0
Study: 34508839

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention to prevent heart failure
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity score
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: E/e' ratio
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: GLS in patients on baseline angiotensin convertase enzyme inhibitors
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: GLS in patients on baseline beta-blockers
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Clinical model based on age, gender, and Charlson score
Number of subjects: 334
Study: 33749798

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 35
Study: 32178813

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) and MyTeachingPartner™ (MTP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 33739461

Group type: EXPERIMENTAL
Intervention: idelalisib and rituximab (IR)
Number of subjects: 149
Study: 32940847

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide 75 mg/m2 orally for 14 days, epirubicin 60 mg/m2 and fluorouracil IV days one and eight for six cycles)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: ddEC/T (dose-dense epirubicin 120 mg/m2 and cyclophosphamide IV every 2 weeks for six cycles with concurrent G-CSF then paclitaxel every 2 weeks for four cycles)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: AC/T (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for four cycles then four cycles q3 weekly paclitaxel 175 mg/m2)
Number of subjects: 2104
Study: 35709551

Group type: EXPERIMENTAL
Intervention: Multifaceted neurological assessment educational program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 55
Study: 32124925

Group type: EXPERIMENTAL
Intervention: Plasma FGF23 levels
Number of subjects: 5253
Study: 32761316

Group type: EXPERIMENTAL
Intervention: Automated pump-delivery device
Number of subjects: 105

Group type: COMPARATOR
Intervention: Manual gravity-drip device
Number of subjects: 105
Study: 33600287

Group type: EXPERIMENTAL
Intervention: Chewing gum after a nitrate-rich meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: No gum chewing (control)
Number of subjects: 20
Study: 34034067

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5-0.75 mg/kg) administered over 1-2 weeks, with four infusions.
Number of subjects: 68
Study: 32152169

Group type: EXPERIMENTAL
Intervention: DeltaGold Tocotrienol 70%
Number of subjects: 0

Group type: COMPARATOR
Intervention: 430 mg olive oil (placebo)
Number of subjects: 0
Study: 35922522

Group type: EXPERIMENTAL
Intervention: Loading dose IV salbutamol (15 mcg/kg, max. 750 mcg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Loading dose IV salbutamol
Number of subjects: 58
Study: 34726262

Group type: EXPERIMENTAL
Intervention: Nemolizumab 60 mg every 4 weeks (Q4W) with concomitant topical treatments
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 33460045

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 34002319

Group type: EXPERIMENTAL
Intervention: WATCHMAN
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AMPLATZER Amulet
Number of subjects: 51
Study: 34810349

Group type: EXPERIMENTAL
Intervention: Diode Laser (DL)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Simvastatin Gel (SG)
Number of subjects: 98
Study: 36476355

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy with mask oxygen after birth (n=48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Carrier oil inhalation (Control group, n=48)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (n=48)
Number of subjects: 96
Study: 33150798

Group type: EXPERIMENTAL
Intervention: Tibolone (TIB) use
Number of subjects: 13110
Study: 32673573

Group type: EXPERIMENTAL
Intervention: Surgical tube drain
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT) application
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine surgical operation (Control)
Number of subjects: 90
Study: 35140195

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg per day from admission to discharge)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 94
Study: 34714194

Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS, 30‐60 mg)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (both amlodipine and nifedipine)
Number of subjects: 418
Study: 32948359

Group type: COMPARATOR
Intervention: 1-day LRD
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 3-day LRD
Number of subjects: 135
Study: 35689457

Group type: EXPERIMENTAL
Intervention: 8-week, six-session web-based relapse prevention program
Number of subjects: 48

Group type: COMPARATOR
Intervention: web-based self-monitoring only (control group)
Number of subjects: 48
Study: 33618694

Group type: EXPERIMENTAL
Intervention: 2D ultrasound
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: 3D ultrasound VOCAL technique
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Nomograms of 2D and 3D fetal thoracic measurements
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Intra- and inter-observer reliability assessment
Number of subjects: 1077
Study: 32857027

Group type: EXPERIMENTAL
Intervention: Collagen-based bioinductive implant
Number of subjects: 30
Study: 36213587

Group type: EXPERIMENTAL
Intervention: Neck and face management in the observation group
Number of subjects: 60
Study: 34022107

Group type: EXPERIMENTAL
Intervention: NAFLD/NASH tweets
Number of subjects: 193747

Group type: EXPERIMENTAL
Intervention: Obesity tweets
Number of subjects: 193747